Know how the loss making Sharon Bio-Medicine is doing at the markets today

Loss making Sharon Bio-Medicine was locked up 20 percent for the second day as the company said it expected to add to sales to the United States and the European Union post the USFDA's inspection of its 2nd plant in less than 2 months.

The USFDA inspected and audited Sharon Bio's formulation plant at Dehradun last week. Earlier the body had examined the company's Tajola unit near Navi Mumbai.

As a consequence, the company is hoping to add active pharma ingredient sales to the US as well as other nations. The move prompted the stock to surge nearly 44 percent in two sessions.

Today, Sharon surged 4.25 rupees, or 20 percent, to 25.60 rupees on the National Stock Exchange, where 50.3 lakh shares were traded versus a one-week average of 4.7 lakh shares

(Image credits: Indiatimes)